

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

Study Number:

Study Sex:

PWG Approval Date:

Version:

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

C11054B-02

Both

See web page for date of PWG Approval

v1.4.3

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Male: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	10	10	10	10	10
Censored	10	10	10	10	10
Early Deaths					
Survivors					
Number Animals Examined Microscopically	10				10
ALIMENTARY SYSTEM					
ESOPHAGUS	(10)	(0)	(0)	(0)	(10)
GALLBLADDER	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(0)	(10)
NECROSIS	2 (20%)				2 (20%)
PANCREAS	(10)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(10)
ATROPHY					1 (10%)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM					
AORTA	(10)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(10)

Study Number: C11054B-02**Test Type:** TOX**Route:** Dosing in Water**Species/Strain:** Mouse/B6C3F1/N**PA03: Non-Neoplastic Lesion Summary with Percent Incidence****Test Compound:** Sulfolane**CAS Number:** 126-33-0**Target Version:** Actions To Be Taken**Date Report Requested:** 11/14/2022**Time Report Requested:** 11:46:37**Lab:** Battelle with CRL

Male: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, CORTEX	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, MEDULLA	(10)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(8)
PITUITARY GLAND	(10)	(0)	(0)	(0)	(10)
THYROID GLAND	(10)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
EPIDIDYMIS	(10)	(0)	(0)	(0)	(10)
PREPUTIAL GLAND	(10)	(0)	(0)	(0)	(10)
PROSTATE	(10)	(0)	(0)	(0)	(10)
SEMINAL VESICLE	(10)	(0)	(0)	(0)	(10)
TESTIS	(10)	(0)	(0)	(0)	(10)
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(0)	(0)	(0)	(10)
THYMUS	(10)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(1)	(0)	(0)	(0)	(3)
SKIN	(10)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(10)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM					
BRAIN	(10)	(0)	(0)	(0)	(10)

Male: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(10)	(0)	(0)	(0)	(10)
NOSE	(10)	(0)	(0)	(0)	(10)
TRACHEA	(10)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM					
EYE	(10)	(0)	(0)	(0)	(10)
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(10)
URINARY SYSTEM					
KIDNEY	(10)	(0)	(0)	(0)	(10)
RENAL TUBULE; CYST					1 (10%)
URINARY BLADDER	(10)	(0)	(0)	(0)	(10)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	10	10	10	10	10
Censored	10	10	10	10	10
Early Deaths					
Survivors					
Number Animals Examined Microscopically	10		1		10
ALIMENTARY SYSTEM					
ESOPHAGUS	(10)	(0)	(0)	(0)	(10)
GALLBLADDER	(9)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(0)	(10)
NECROSIS	1 (10%)				
PANCREAS	(10)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(10)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM					
AORTA	(10)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(10)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, CORTEX	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, MEDULLA	(10)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(9)
PITUITARY GLAND	(10)	(0)	(0)	(0)	(10)
THYROID GLAND	(10)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
CLITORAL GLAND	(10)	(0)	(0)	(0)	(10)
OVARY	(10)	(0)	(0)	(0)	(10)
UTERUS	(10)	(0)	(1)	(0)	(10)
ENDOMETRIUM; HYPERPLASIA; FOCAL			1 (100%)		
UTERUS, CERVIX	(10)	(0)	(0)	(0)	(10)
VAGINA	(10)	(0)	(0)	(0)	(10)
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(0)	(0)	(0)	(10)
THYMUS	(10)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(10)	(0)	(0)	(0)	(10)
SKIN	(10)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(10)	(0)	(0)	(0)	(10)

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
NERVOUS SYSTEM					
BRAIN	(10)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM					
LUNG	(10)	(0)	(0)	(0)	(10)
NOSE	(10)	(0)	(0)	(0)	(10)
TRACHEA	(10)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM					
EYE	(10)	(0)	(0)	(0)	(10)
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(10)
URINARY SYSTEM					
KIDNEY	(10)	(0)	(0)	(0)	(10)
RENAL TUBULE; CYST					1 (10%)
URINARY BLADDER	(10)	(0)	(0)	(0)	(10)

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	50	50	50	50	50
Censored					
Early Deaths					
Found Dead	11	10	10	14	13
Sacrificed, Moribund	5	12	5	4	8
Survivors					
Scheduled Sacrifice, Terminal	34	28	35	32	29
Number Animals Examined Microscopically	50	50	50	50	50

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ALIMENTARY SYSTEM					
ESOPHAGUS	(50)	(50)	(50)	(49)	(50)
GALLBLADDER	(47)	(47)	(45)	(47)	(46)
CYST					1 (2%)
INTESTINE, LARGE, CECUM	(50)	(50)	(50)	(50)	(50)
Serosa; Inflammation; Chronic	1 (2%)				
INTESTINE, LARGE, COLON	(50)	(50)	(49)	(50)	(49)
Serosa; Inflammation; Chronic	1 (2%)				
INTESTINE, LARGE, RECTUM	(50)	(50)	(50)	(50)	(49)
Serosa; Inflammation; Chronic	1 (2%)				
INTESTINE, SMALL, DUODENUM	(50)	(50)	(50)	(50)	(50)
Serosa; Inflammation; Chronic	1 (2%)				
INTESTINE, SMALL, ILEUM	(49)	(50)	(49)	(50)	(50)
Serosa; Inflammation; Chronic	1 (2%)		1 (2%)		
ULCER					1 (2%)
INTESTINE, SMALL, JEJUNUM	(50)	(50)	(50)	(50)	(50)
Lymphocyte; Hyperplasia	1 (2%)				
Infiltration, Cellular; Histocyte	1 (2%)	1 (2%)			
Serosa; Inflammation; Chronic	1 (2%)				
Inflammation; Suppurative	1 (2%)				
ULCER					1 (2%)
LIVER	(50)	(50)	(50)	(50)	(50)
ANGIECTASIS			1 (2%)	1 (2%)	
BASOPHILIC FOCUS	3 (6%)	1 (2%)	3 (6%)	1 (2%)	2 (4%)
CLEAR CELL FOCUS; MULTIPLE	15 (30%)	9 (18%)	12 (24%)	9 (18%)	15 (30%)
CLEAR CELL FOCUS	10 (20%)	10 (20%)	10 (20%)	4 (8%)	5 (10%)
BILE DUCT; CYST	1 (2%)	1 (2%)	4 (8%)		
EOSINOPHILIC FOCUS; MULTIPLE	21 (42%)	12 (24%)	8 (16%)	16 (32%)	17 (34%)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
EOSINOPHILIC FOCUS	11 (22%)	13 (26%)	18 (36%)	14 (28%)	12 (24%)
EXTRAMEDULLARY HEMATOPOIESIS; INCREASED	2 (4%)				1 (2%)
FATTY CHANGE; DIFFUSE	2 (4%)	3 (6%)	2 (4%)		1 (2%)
FATTY CHANGE; FOCAL	9 (18%)	2 (4%)	5 (10%)	3 (6%)	8 (16%)
HEMATOCYST		1 (2%)			
HEMATOPOIETIC CELL PROLIFERATION					1 (2%)
MIXED CELL FOCUS; MULTIPLE	2 (4%)	5 (10%)	9 (18%)	5 (10%)	2 (4%)
MIXED CELL FOCUS	4 (8%)	13 (26%)	6 (12%)	8 (16%)	5 (10%)
NECROSIS	2 (4%)	6 (12%)		2 (4%)	2 (4%)
TENSION LIPIDOSIS	2 (4%)	3 (6%)	2 (4%)	1 (2%)	
VENULE; THROMBUS					1 (2%)
THROMBUS				1 (2%)	
MESENTERY	(1)	(2)	(2)	(4)	(2)
HEMATOCYST			1 (50%)		
FAT; NECROSIS		1 (50%)	1 (50%)	4 (100%)	
PANCREAS	(50)	(50)	(50)	(49)	(50)
DUCT; CYST			1 (2%)		
SALIVARY GLAND	(50)	(50)	(50)	(50)	(50)
STOMACH, FORESTOMACH	(50)	(50)	(50)	(50)	(50)
ACCESSORY ADRENOCORTICAL NODULE				1 (2%)	
SQUAMOUS EPITHELIUM; HYPERPLASIA		1 (2%)	2 (4%)		
HYPERPLASIA				2 (4%)	
INFLAMMATION; CHRONIC			1 (2%)	1 (2%)	
ULCER	1 (2%)				1 (2%)
STOMACH, GLANDULAR	(50)	(50)	(50)	(50)	(50)
EPITHELIAL CELL; HYPERPLASIA		1 (2%)			
EPITHELIUM; HYPERPLASIA		1 (2%)			
INFLAMMATION; CHRONIC			1 (2%)		

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
MINERAL ULCER	4 (8%)	8 (16%) 1 (2%)	8 (16%)	6 (12%)	6 (12%)
CARDIOVASCULAR SYSTEM					
AORTA	(50)	(50)	(50)	(50)	(50)
HEART	(50)	(50)	(50)	(50)	(50)
VALVE; BACTERIA			1 (2%)		2 (4%)
BACTERIA					3 (6%)
CARDIOMYOPATHY		1 (2%)	2 (4%)		
ARTERIOLE; INFLAMMATION; CHRONIC	1 (2%)				
MYOCARDIUM; INFLAMMATION; SUPPURATIVE	1 (2%)				
VALVE; INFLAMMATION; CHRONIC					2 (4%)
VALVE; INFLAMMATION; SUPPURATIVE	1 (2%)				
ARTERIOLE; MINERAL			1 (2%)		
MINERAL	1 (2%)	2 (4%)			
MYOCARDIUM; VACUOLATION, CYTOPLASMIC		1 (2%)			

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(47)	(50)	(50)	(50)	(50)
CYST				1 (2%)	1 (2%)
CAPSULE; INFLAMMATION; CHRONIC				1 (2%)	
ADRENAL GLAND, CORTEX	(47)	(50)	(50)	(50)	(50)
HYPERPLASIA; FOCAL					2 (4%)
HYPERTROPHY; FOCAL		2 (4%)		1 (2%)	3 (6%)
ADRENAL GLAND, MEDULLA	(47)	(50)	(49)	(48)	(50)
ISLETS, PANCREATIC	(50)	(50)	(50)	(49)	(50)
HYPERPLASIA			1 (2%)		
PARATHYROID GLAND	(38)	(36)	(39)	(42)	(41)
CYST			1 (3%)	1 (2%)	1 (2%)
PITUITARY GLAND	(43)	(47)	(47)	(47)	(47)
PARS DISTALIS; CYST		1 (2%)	2 (4%)	1 (2%)	3 (6%)
PARS DISTALIS; HYPERPLASIA	1 (2%)		1 (2%)		
THYROID GLAND	(50)	(50)	(49)	(49)	(50)
C-CELL; HYPERPLASIA					1 (2%)
FOLLICLES; EPITHELIUM; HYPERPLASIA				2 (4%)	
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
GENITAL SYSTEM					
COAGULATING GLAND	(0)	(0)	(1)	(0)	(0)
CYST			1 (100%)		
EPIDIDYMIS	(50)	(50)	(50)	(50)	(50)
EXFOLIATED GERM CELL	1 (2%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)
HYOSPERMIA				1 (2%)	
SEROSEA; INFLAMMATION; CHRONIC				2 (4%)	1 (2%)
PENIS	(0)	(1)	(0)	(0)	(0)
PROLAPSE		1 (100%)			
PREPUTIAL GLAND	(50)	(49)	(50)	(49)	(49)
ABSCESS					1 (2%)
CYST		1 (2%)			
INFLAMMATION; SUPPURATIVE	1 (2%)				
PROSTATE	(50)	(50)	(50)	(50)	(50)
ACINUS; ATROPHY			1 (2%)		
ATROPHY				1 (2%)	
INFLAMMATION; CHRONIC	2 (4%)				2 (4%)
INFLAMMATION; SUPPURATIVE	2 (4%)				
SEMINAL VESICLE	(50)	(50)	(50)	(50)	(50)
ATROPHY			2 (4%)		1 (2%)
HEMORRHAGE	4 (8%)	1 (2%)	2 (4%)	1 (2%)	
INFLAMMATION; CHRONIC	2 (4%)	1 (2%)		4 (8%)	2 (4%)
INFLAMMATION; CHRONIC-ACTIVE	1 (2%)				
INFLAMMATION; SUPPURATIVE	1 (2%)				
NECROSIS	1 (2%)				
TESTIS	(50)	(50)	(50)	(50)	(50)
GERMINAL EPITHELIUM; ATROPHY	1 (2%)	1 (2%)	2 (4%)	2 (4%)	6 (12%)
GERMINAL EPITHELIUM; DEGENERATION	1 (2%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
EXFOLIATED GERM CELL				1 (2%)	
HEMATOLYMPHOID SYSTEM					
BONE MARROW	(50)	(50)	(50)	(50)	(50)
LYMPH NODE	(2)	(0)	(0)	(1)	(2)
LYMPH NODE, BRONCHIAL	(2)	(1)	(1)	(1)	(0)
LYMPH NODE, MANDIBULAR	(43)	(50)	(47)	(45)	(47)
LYMPHOCYTE; HYPERPLASIA			1 (2%)		
INFILTRATION, CELLULAR; HISTIOCYTE			1 (2%)		
LYMPH NODE, MEDIASTINAL	(0)	(0)	(0)	(2)	(0)
LYMPH NODE, MESENTERIC	(50)	(48)	(47)	(49)	(47)
CONGESTION					1 (2%)
EXTRAMEDULLARY HEMATOPOIESIS; INCREASED		1 (2%)			1 (2%)
HEMATOCYST			1 (2%)		
LYMPHOCYTE; HYPERPLASIA	1 (2%)				
INFILTRATION, CELLULAR; HISTIOCYTE		1 (2%)	1 (2%)	1 (2%)	
SPLEEN	(49)	(50)	(50)	(50)	(50)
ATROPHY		1 (2%)			
EXTRAMEDULLARY HEMATOPOIESIS; INCREASED	1 (2%)		1 (2%)		2 (4%)
LYMPHOCYTE; HYPERPLASIA	1 (2%)				
INFILTRATION, CELLULAR; HISTIOCYTE			1 (2%)	1 (2%)	
NECROSIS	1 (2%)				
THYMUS	(46)	(46)	(48)	(45)	(47)
ATROPHY	2 (4%)			1 (2%)	1 (2%)
CYST		2 (4%)		1 (2%)	
LYMPHOCYTE; HYPERPLASIA					1 (2%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(0)	(1)	(1)	(2)	(1)
SKIN	(50)	(50)	(50)	(50)	(50)
ABSCESS		1 (2%)			
EDEMA				1 (2%)	
EPIDERMAL INCLUSION CYST				1 (2%)	
FIBROSIS		1 (2%)			
SEBACEOUS GLAND; HYPERPLASIA	1 (2%)				1 (2%)
NECROSIS					1 (2%)
ULCER					1 (2%)
TAIL	(0)	(0)	(0)	(0)	(1)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(50)	(50)	(50)	(50)	(50)
SKELETAL MUSCLE	(2)	(2)	(1)	(0)	(3)
NERVOUS SYSTEM					
BRAIN	(50)	(50)	(50)	(50)	(50)
EPIDERMAL INCLUSION CYST				1 (2%)	
HEMORRHAGE		1 (2%)			
HYDROCEPHALUS		1 (2%)			
MENINGES; INFLAMMATION; CHRONIC	1 (2%)				1 (2%)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(50)	(50)	(50)	(50)	(50)
HEMATOCYST		1 (2%)			
HEMORRHAGE			2 (4%)		
EPITHELIUM; ALVEOLAR/BRONCHIOLAR; HYPERPLASIA	3 (6%)	9 (18%)	3 (6%)	8 (16%)	5 (10%)
INFILTRATION, CELLULAR; HISTIOCYTE			1 (2%)		
ALVEOLUS; INFLAMMATION; CHRONIC					1 (2%)
BRONCHUS; INFLAMMATION; CHRONIC				1 (2%)	
MEDIASTINUM; INFLAMMATION; CHRONIC					1 (2%)
NOSE	(50)	(50)	(50)	(50)	(50)
RESPIRATORY EPITHELIUM; INFLAMMATION; SUPPURATIVE	3 (6%)	3 (6%)			
TRACHEA	(50)	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM					
EYE	(50)	(50)	(50)	(50)	(50)
CORNEA; INFLAMMATION; CHRONIC			1 (2%)		1 (2%)
PHTHISIS BULBI	2 (4%)			1 (2%)	1 (2%)
HARDERIAN GLAND	(50)	(50)	(50)	(49)	(50)
HYPERPLASIA	3 (6%)	6 (12%)		4 (8%)	4 (8%)
ZYMBALS GLAND	(0)	(0)	(1)	(0)	(0)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
URINARY SYSTEM					
KIDNEY	(50)	(50)	(50)	(49)	(50)
AMYLOID			1 (2%)		
ANGIECTASIS			1 (2%)		
BACTERIA	1 (2%)				4 (8%)
CHRONIC PROGRESSIVE NEPHROPATHY	46 (92%)	40 (80%)	40 (80%)	39 (80%)	46 (92%)
RENAL TUBULE; CYST	1 (2%)	4 (8%)	5 (10%)	4 (8%)	5 (10%)
PELVIS; DILATION		2 (4%)	2 (4%)	2 (4%)	
HEMORRHAGE					1 (2%)
RENAL TUBULE; HYALINE DROPLET ACCUMULATION				2 (4%)	2 (4%)
RENAL TUBULE; HYPERTROPHY				1 (2%)	
INFARCT	2 (4%)				
ARTERIOLE; INFLAMMATION; CHRONIC-ACTIVE				1 (2%)	
INTERSTITIUM; INFLAMMATION; CHRONIC	1 (2%)				1 (2%)
INTERSTITIUM; INFLAMMATION; SUPPURATIVE					2 (4%)
PAPILLA; INFLAMMATION; CHRONIC-ACTIVE					1 (2%)
PELVIS; INFLAMMATION; CHRONIC					1 (2%)
PELVIS; INFLAMMATION; SUPPURATIVE	2 (4%)				
PAPILLA; MINERAL		1 (2%)			
MINERAL		1 (2%)			
PAPILLA; NECROSIS			1 (2%)		
RENAL TUBULE; PIGMENT		2 (4%)	1 (2%)		
VEIN; THROMBUS	1 (2%)				
VENULE; THROMBUS	1 (2%)				1 (2%)
URETER	(0)	(0)	(0)	(2)	(0)
DILATION				2 (100%)	
URINARY BLADDER	(50)	(50)	(50)	(50)	(50)
DILATION			1 (2%)		

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
UROTHELIUM; HYPERPLASIA		1 (2%)		1 (2%)	

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	50	50	50	50	50
Censored					
Early Deaths					
Found Dead	13	9	11	8	11
Sacrificed, Moribund	2	2	5	8	2
Survivors					
Scheduled Sacrifice, Terminal	35	39	34	34	37
Number Animals Examined Microscopically	50	50	50	50	50

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

	Female: Core Animals				
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ALIMENTARY SYSTEM					
ESOPHAGUS	(50)	(50)	(50)	(49)	(50)
NECROSIS	1 (2%)				
GALLBLADDER	(49)	(49)	(46)	(47)	(47)
CYST					1 (2%)
INTESTINE, LARGE, CECUM	(50)	(50)	(50)	(49)	(50)
INTESTINE, LARGE, COLON	(50)	(50)	(50)	(50)	(50)
INTESTINE, LARGE, RECTUM	(49)	(50)	(49)	(48)	(50)
INFLAMMATION; CHRONIC					1 (2%)
INTESTINE, SMALL, DUODENUM	(50)	(50)	(50)	(50)	(50)
INFLAMMATION; CHRONIC					1 (2%)
INTESTINE, SMALL, ILEUM	(49)	(49)	(50)	(50)	(50)
INFILTRATION, CELLULAR; HISTIOCYTE	1 (2%)				
INFLAMMATION; SUPPURATIVE	1 (2%)				
INTESTINE, SMALL, JEJUNUM	(50)	(50)	(50)	(50)	(50)
INFILTRATION, CELLULAR; HISTIOCYTE	1 (2%)				
INFLAMMATION; SUPPURATIVE	1 (2%)				
LIVER	(50)	(50)	(50)	(50)	(50)
ANGIECTASIS	2 (4%)	1 (2%)		2 (4%)	
BASOPHILIC FOCUS; MULTIPLE			1 (2%)		
BASOPHILIC FOCUS	2 (4%)				
CLEAR CELL FOCUS; MULTIPLE			1 (2%)	1 (2%)	1 (2%)
CLEAR CELL FOCUS	4 (8%)	4 (8%)	5 (10%)	3 (6%)	9 (18%)
BILE DUCT; CYST					1 (2%)
BILE DUCT; EPITHELIUM; CYTOPLASMIC ALTERATION	1 (2%)		1 (2%)		
CENTRIOBULAR; HEPATOCYTE; DEGENERATION	1 (2%)				
EOSINOPHILIC FOCUS; MULTIPLE	5 (10%)	4 (8%)	7 (14%)	6 (12%)	3 (6%)
EOSINOPHILIC FOCUS	14 (28%)	10 (20%)	9 (18%)	6 (12%)	6 (12%)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
EXTRAMEDULLARY HEMATOPOIESIS; INCREASED		2 (4%)	2 (4%)	1 (2%)	
FATTY CHANGE; DIFFUSE	1 (2%)	1 (2%)	3 (6%)	1 (2%)	
FATTY CHANGE; FOCAL	1 (2%)	5 (10%)	8 (16%)	11 (22%)	2 (4%)
PERIPORTAL; FIBROSIS	1 (2%)				
HEMATOCYST			1 (2%)		
BILE DUCT; EPITHELIUM; HYPERPLASIA			1 (2%)		
PERIPORTAL; INFLAMMATION; CHRONIC	1 (2%)		1 (2%)		
INFLAMMATION; CHRONIC				1 (2%)	1 (2%)
MINERAL			1 (2%)		
MIXED CELL FOCUS; MULTIPLE	1 (2%)	5 (10%)	4 (8%)	2 (4%)	
MIXED CELL FOCUS	5 (10%)	8 (16%)	8 (16%)	4 (8%)	5 (10%)
NECROSIS	1 (2%)	1 (2%)	2 (4%)		1 (2%)
TENSION LIPIDOSIS	4 (8%)	3 (6%)	5 (10%)		4 (8%)
VENULE; THROMBUS					1 (2%)
MESENTERY	(8)	(2)	(7)	(13)	(9)
INFLAMMATION; CHRONIC					1 (11%)
FAT; NECROSIS	6 (75%)	2 (100%)	7 (100%)	9 (69%)	4 (44%)
PANCREAS	(50)	(50)	(49)	(50)	(50)
ACINUS; ATROPHY	1 (2%)	1 (2%)			1 (2%)
DUCT; DILATION	2 (4%)				
INFLAMMATION; CHRONIC	1 (2%)				
SALIVARY GLAND	(50)	(49)	(50)	(50)	(49)
STOMACH, FORESTOMACH	(50)	(50)	(50)	(50)	(50)
SQUAMOUS EPITHELIUM; HYPERPLASIA	1 (2%)			1 (2%)	
INFILTRATION, CELLULAR; HISTIOCYTE		1 (2%)			
MINERAL					1 (2%)
ULCER				1 (2%)	
STOMACH, GLANDULAR	(50)	(50)	(50)	(50)	(50)

Study Number: C11054B-02**Test Type:** TOX**Route:** Dosing in Water**Species/Strain:** Mouse/B6C3F1/N**PA03: Non-Neoplastic Lesion Summary with Percent Incidence****Test Compound:** Sulfolane**CAS Number:** 126-33-0**Target Version:** Actions To Be Taken**Date Report Requested:** 11/14/2022**Time Report Requested:** 11:46:37**Lab:** Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
INFLAMMATION; CHRONIC			1 (2%)		2 (4%)
METAPLASIA; SQUAMOUS			1 (2%)		
MINERAL	4 (8%)	10 (20%)	9 (18%)	5 (10%)	7 (14%)
ULCER				1 (2%)	
VACUOLATION, CYTOPLASMIC				1 (2%)	
CARDIOVASCULAR SYSTEM					
AORTA	(50)	(50)	(50)	(50)	(50)
MINERAL	1 (2%)		1 (2%)		
HEART	(50)	(50)	(50)	(50)	(50)
ATROPHY				1 (2%)	
BACTERIA	1 (2%)			1 (2%)	
CARDIOMYOPATHY			1 (2%)	1 (2%)	
FIBROSIS				1 (2%)	
ARTERIOLE; INFLAMMATION; CHRONIC			1 (2%)	1 (2%)	
ARTERY; INFLAMMATION; CHRONIC	1 (2%)				
EPICARDIUM; INFLAMMATION; CHRONIC				1 (2%)	
MYOCARDIUM; INFLAMMATION; CHRONIC				2 (4%)	
MINERAL				1 (2%)	
ATRIUM; THROMBUS		1 (2%)			
THROMBUS			2 (4%)		

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(48)	(50)	(50)	(48)	(49)
CYST					1 (2%)
CAPSULE; INFLAMMATION; CHRONIC				1 (2%)	
ADRENAL GLAND, CORTEX	(48)	(50)	(50)	(48)	(49)
AMYLOID					1 (2%)
ANGIECTASIS					1 (2%)
HYPERPLASIA; FOCAL			1 (2%)		
NECROSIS					1 (2%)
VACUOLATION, CYTOPLASMIC					1 (2%)
ADRENAL GLAND, MEDULLA	(48)	(50)	(50)	(47)	(49)
HYPERPLASIA; FOCAL		1 (2%)			
ISLETS, PANCREATIC	(50)	(50)	(50)	(50)	(50)
PARATHYROID GLAND	(35)	(32)	(38)	(31)	(24)
C-CELL; ECTOPIC TISSUE			1 (3%)		
PITUITARY GLAND	(46)	(47)	(47)	(44)	(42)
PARS DISTALIS; ANGIECTASIS		1 (2%)	1 (2%)	3 (7%)	
PARS DISTALIS; CYST					1 (2%)
PARS DISTALIS; HYPERPLASIA	3 (7%)	5 (11%)	9 (19%)	7 (16%)	2 (5%)
THYROID GLAND	(49)	(48)	(50)	(50)	(49)
CYST; CONGENITAL	3 (6%)				
C-CELL; HYPERPLASIA		1 (2%)	1 (2%)		
FOLLICLES; EPITHELIUM; HYPERPLASIA	1 (2%)		2 (4%)		
INFLAMMATION; GRANULOMATOUS			1 (2%)		
INFLAMMATION; SUPPURATIVE					1 (2%)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
GENITAL SYSTEM					
CLITORAL GLAND	(43)	(45)	(43)	(46)	(45)
OVARY	(48)	(46)	(47)	(48)	(49)
ANGIECTASIS			1 (2%)		
FOLLICLES; CYST	2 (4%)	9 (20%)	3 (6%)	11 (23%)	9 (18%)
RETE OVARI; CYST	1 (2%)				
HEMATOCYST			2 (4%)		
PERIOVARIAN TISSUE; INFLAMMATION; CHRONIC				1 (2%)	
PARAOVARIAN CYST					1 (2%)
UTERUS	(50)	(50)	(50)	(50)	(50)
ARTERIOLE; AMYLOID					1 (2%)
ANGIECTASIS	1 (2%)	2 (4%)	2 (4%)	1 (2%)	2 (4%)
DILATION	2 (4%)	1 (2%)	3 (6%)	1 (2%)	1 (2%)
ENDOMETRIUM; HYPERPLASIA; CYSTIC	34 (68%)	40 (80%)	38 (76%)	37 (74%)	41 (82%)
STROMA; HYPERPLASIA		1 (2%)			
INFLAMMATION; SUPPURATIVE	2 (4%)	2 (4%)	3 (6%)		3 (6%)
ENDOMETRIUM; METAPLASIA; SQUAMOUS	2 (4%)	1 (2%)			1 (2%)
UTERUS, CERVIX	(50)	(50)	(50)	(50)	(50)
VAGINA	(50)	(50)	(50)	(50)	(50)

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HEMATOLYMPHOID SYSTEM					
BONE MARROW	(50)	(50)	(50)	(50)	(50)
LYMPH NODE	(1)	(2)	(4)	(2)	(1)
RENAL; AMYLOID					1 (100%)
LUMBAR; HEMATOCYST		1 (50%)		1 (50%)	
LYMPH NODE, AXILLARY	(2)	(0)	(1)	(0)	(0)
LYMPH NODE, BRONCHIAL	(1)	(1)	(3)	(1)	(2)
LYMPH NODE, MANDIBULAR	(48)	(48)	(48)	(46)	(45)
LYMPHOCYTE; HYPERPLASIA			2 (4%)		
INFILTRATION, CELLULAR; HISTIOCYTE		1 (2%)			2 (4%)
INFILTRATION, CELLULAR; NEUTROPHIL				1 (2%)	
LYMPH NODE, MEDIASTINAL	(2)	(2)	(3)	(2)	(0)
INFILTRATION, CELLULAR; HISTIOCYTE	2 (100%)	1 (50%)			
LYMPH NODE, MESENTERIC	(48)	(50)	(48)	(49)	(48)
AMYLOID					1 (2%)
LYMPHOCYTE; HYPERPLASIA			2 (4%)		
HYPERPLASIA; PLASMA CELL	2 (4%)		1 (2%)	1 (2%)	
INFILTRATION, CELLULAR; HISTIOCYTE	4 (8%)	1 (2%)	1 (2%)		
SPLEEN	(50)	(50)	(49)	(50)	(50)
ANGIECTASIS	1 (2%)				
EXTRAMEDULLARY HEMATOPOIESIS; INCREASED	4 (8%)	2 (4%)	5 (10%)	3 (6%)	1 (2%)
INFILTRATION, CELLULAR; HISTIOCYTE			1 (2%)		
INFILTRATION, CELLULAR; PLASMA CELL				1 (2%)	
THYMUS	(47)	(50)	(48)	(48)	(49)
LYMPHOCYTE; HYPERPLASIA		1 (2%)	1 (2%)		
INFILTRATION, CELLULAR; HISTIOCYTE	1 (2%)				1 (2%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(48)	(50)	(49)	(50)	(49)
DUCT; DILATION	1 (2%)	2 (4%)			
LOBULOALVEOLAR; HYPERPLASIA		1 (2%)			
SKIN	(50)	(50)	(50)	(50)	(49)
EPIDERMAL INCLUSION CYST			1 (2%)		
HYPERKERATOSIS				1 (2%)	
INFLAMMATION; GRANULOMATOUS			1 (2%)		
ULCER	1 (2%)		1 (2%)	2 (4%)	
MUSCULOSKELETAL SYSTEM					
BONE	(1)	(2)	(1)	(0)	(1)
BONE, FEMUR	(50)	(50)	(50)	(50)	(50)
SKELETAL MUSCLE	(1)	(2)	(1)	(3)	(1)
NERVOUS SYSTEM					
BRAIN	(50)	(50)	(50)	(50)	(50)
ARTERIOLE; LATERAL VENTRICLE; INFLAMMATION; CHRONIC			1 (2%)		
MENINGES; INFLAMMATION; CHRONIC				1 (2%)	
INFLAMMATION; CHRONIC	1 (2%)				
NERVE, SCIATIC	(0)	(0)	(1)	(1)	(1)
NERVE, TRIGEMINAL	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, CERVICAL	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, LUMBAR	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, THORACIC	(0)	(0)	(1)	(1)	(1)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:46:37
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(50)	(50)	(50)	(50)	(50)
ARTERIOLE; EMBOLUS			1 (2%)		
HEMORRHAGE		1 (2%)			1 (2%)
EPITHELIUM; ALVEOLAR/BRONCHIOLAR; HYPERPLASIA	3 (6%)	4 (8%)	5 (10%)		3 (6%)
PLEURA; INFLAMMATION; CHRONIC				1 (2%)	
VENULE; INFLAMMATION; CHRONIC					1 (2%)
ARTERIOLE; MINERAL			1 (2%)		
NOSE	(50)	(50)	(50)	(50)	(50)
RESPIRATORY EPITHELIUM; INFLAMMATION; CHRONIC					1 (2%)
RESPIRATORY EPITHELIUM; INFLAMMATION; SUPPURATIVE					1 (2%)
TRACHEA	(49)	(50)	(50)	(50)	(50)
INFILTRATION, CELLULAR; NEUTROPHIL					1 (2%)
SPECIAL SENSES SYSTEM					
EAR	(0)	(0)	(0)	(1)	(0)
PINNA; ULCER				1 (100%)	
EYE	(48)	(50)	(50)	(49)	(50)
PHTHISIS BULBI		1 (2%)		1 (2%)	
HARDERIAN GLAND	(50)	(50)	(49)	(50)	(49)
ATROPHY		1 (2%)			
HYPERPLASIA	1 (2%)	5 (10%)	4 (8%)	4 (8%)	3 (6%)
INFLAMMATION; CHRONIC	1 (2%)				

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
URINARY SYSTEM					
KIDNEY	(50)	(50)	(50)	(50)	(50)
GLOMERULUS; AMYLOID			1 (2%)		1 (2%)
BACTERIA				1 (2%)	
CHRONIC PROGRESSIVE NEPHROPATHY	23 (46%)	19 (38%)	22 (44%)	30 (60%)	31 (62%)
PELVIS; DILATION			1 (2%)		1 (2%)
RENAL TUBULE; HYALINE DROPLET ACCUMULATION	1 (2%)				1 (2%)
HYALINE DROPLET ACCUMULATION				1 (2%)	
INFARCT			1 (2%)		1 (2%)
INTERSTITIUM; INFLAMMATION; CHRONIC					1 (2%)
INFLAMMATION; CHRONIC					1 (2%)
MINERAL			1 (2%)		
PAPILLA; NECROSIS	1 (2%)				1 (2%)
URINARY BLADDER	(49)	(50)	(50)	(49)	(50)
UROTHELIUM; HYPERPLASIA				1 (2%)	1 (2%)
MUCOSA; INFLAMMATION; CHRONIC				1 (2%)	

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:46:37

Lab: Battelle with CRL

LEGEND

Censored animals are animals not in one of the other disposition categories that are removed prior to the end of the study. The censored animals are included in the pathology data if microscopic examination of tissues was performed.

Number of animals examined given for each tissue.

Number of animals with observation reported with percent incidence in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

**** END OF REPORT ****